Advances in prostate cancer treatment by Prof Louise Emmett


Share on linkedin

Statistics show prostate cancer is the most commonly diagnosed cancer in Australian men, with 20,000 diagnoses and close to 3,300 deaths each year? However, prostate cancer has one of the highest survival rates of all cancers, with 95% of men likely to survive five years or more. About 220,000 Australian men are alive today after a diagnosis of prostate cancer.

This September, Prostate Cancer Awareness Month, we celebrate the ongoing work of Prof Louise Emmett, Director of Theranostics and Nuclear medicine at St Vincent’s Hospital Sydney and a previous grant recipient of St Vincent’s Clinic Foundation. Her randomised multi-site clinical trial around Australia called ENZA-p combined two highly effective targeted treatments, enzalutamide and Lutetium PSMA, with a goal to maximise their effect with a double attack against cancer cells.

The ENZA-p research team are learning and predicting which combination of drugs will work best for each patient, when to use the treatment and intensify it for optimal response. The goal is to provide each patient with individualized treatment to improve the chances of successful outcomes.

Prof Louise Emmett’s research is a game changer and one that aims to shift the paradigm of prostate cancer treatment to deliver better quality of life and survival rates for patients.

Prostate Cancer Research by Prof Louise Emmett

“Attacking prostate cancer is a game of chess and takes quite a bit of masterminding to plan how to attack the tumour.  You must anticipate its next move and design the best way to block it.”